Subsidiary TFA003 of Zhejiang Conba Pharmaceutical (600572.SH) obtained the drug clinical trial approval notice.

17:17 04/02/2026

Kangenbei (600572.SH) announced that its wholly-owned subsidiary Hangzhou Kangenbei Pharmaceutical Co., Ltd. (referred to as "Hangzhou Kangenbei") recently received the "Notice of Approval for Drug Clinical Trial Batch" of TFA003 tablets issued by the National Medical Products Administration.

Zhejiang Conba Pharmaceutical (600572.SH) announced that its wholly-owned subsidiary Hangzhou Zhejiang Conba Pharmaceutical Co., Ltd. (referred to as "Hangzhou Zhejiang Conba Pharmaceutical") has recently received the "Drug Clinical Trial Approval Notice" for TFA003 tablets issued by the National Medical Products Administration. Approval conclusion: According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, the TFA003 tablets submitted on October 16, 2025 meet the requirements for drug registration. On the basis of further improving the clinical trial plan, it has been approved to conduct clinical trials for diabetic kidney disease.

HKE HOLDINGS (01726) plans to offer 100 million shares for sale, raising approximately HK$1.19 billion.

Leshan Giantstar Farming & Husbandry Corporation's (603477.SH) application for additional share issuance has been approved by the Shanghai Stock Exchange.

WINFULL GP (00183) intends to sell its Japanese properties for 280 million yen.

HKE HOLDINGS (01726) plans to offer 100 million shares for sale, raising approximately HK$1.19 billion.

Leshan Giantstar Farming & Husbandry Corporation's (603477.SH) application for additional share issuance has been approved by the Shanghai Stock Exchange.

WINFULL GP (00183) intends to sell its Japanese properties for 280 million yen.